Research Analysts Set Expectations for BMRN FY2025 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer expects that the biotechnology company will earn $3.09 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $90.00 price objective on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.50 per share.

Several other brokerages have also recently commented on BMRN. Canaccord Genuity Group dropped their target price on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating for the company in a research report on Wednesday, October 30th. UBS Group upped their target price on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Wedbush upgraded BioMarin Pharmaceutical to a “strong-buy” rating in a research note on Monday, November 4th. Citigroup dropped their price objective on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Finally, Robert W. Baird decreased their target price on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $94.20.

BioMarin Pharmaceutical Stock Up 1.6 %

BMRN stock opened at $62.53 on Wednesday. The company has a market cap of $11.92 billion, a PE ratio of 37.44, a price-to-earnings-growth ratio of 0.54 and a beta of 0.29. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical has a 52 week low of $60.63 and a 52 week high of $94.85. The business has a 50-day simple moving average of $65.39 and a 200 day simple moving average of $74.15.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). The business had revenue of $746.00 million during the quarter, compared to analyst estimates of $703.37 million. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.26 earnings per share.

Insider Activity

In other news, EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total value of $350,300.86. Following the completion of the transaction, the executive vice president now directly owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.85% of the company’s stock.

Institutional Trading of BioMarin Pharmaceutical

Large investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new position in shares of BioMarin Pharmaceutical during the 3rd quarter valued at $28,000. TD Private Client Wealth LLC raised its holdings in shares of BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 186 shares during the period. Meeder Asset Management Inc. raised its holdings in shares of BioMarin Pharmaceutical by 920.8% during the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 663 shares during the period. GAMMA Investing LLC grew its stake in shares of BioMarin Pharmaceutical by 56.1% in the 3rd quarter. GAMMA Investing LLC now owns 782 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 281 shares during the period. Finally, True Wealth Design LLC grew its stake in shares of BioMarin Pharmaceutical by 13,400.0% in the 3rd quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 804 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.